Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team.

PubWeight™: 1.20‹?› | Rank: Top 10%

🔗 View Article (PMID 24552242)

Published in Am J Respir Crit Care Med on May 01, 2014

Authors

Jørgen Vestbo1, Alvar Agusti, Emiel F M Wouters, Per Bakke, Peter M A Calverley, Bartolome Celli, Harvey Coxson, Courtney Crim, Lisa D Edwards, Nicholas Locantore, David A Lomas, William MacNee, Bruce Miller, Stephen I Rennard, Edwin K Silverman, Julie C Yates, Ruth Tal-Singer, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Study Investigators

Author Affiliations

1: 1 Department of Respiratory Medicine, Odense University Hospital, and Clinical Institute, University of Southern Denmark, Odense, Denmark.

Associated clinical trials:

Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints (ECLIPSE) | NCT00292552

Articles citing this

Clinical and Immunological Factors in Emphysema Progression. Five-Year Prospective Longitudinal Exacerbation Study of Chronic Obstructive Pulmonary Disease (LES-COPD). Am J Respir Crit Care Med (2015) 1.50

Biomarkers of progression of chronic obstructive pulmonary disease (COPD). J Thorac Dis (2014) 1.14

Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet (2015) 1.11

The science of clinical practice: disease diagnosis or patient prognosis? Evidence about "what is likely to happen" should shape clinical practice. BMC Med (2015) 1.01

A review of national guidelines for management of COPD in Europe. Eur Respir J (2016) 0.99

Synergy-COPD: a systems approach for understanding and managing chronic diseases. J Transl Med (2014) 0.94

Should the diagnosis of COPD be based on a single spirometry test? NPJ Prim Care Respir Med (2016) 0.86

Neutrophil extracellular trap (NET) formation characterises stable and exacerbated COPD and correlates with airflow limitation. Respir Res (2015) 0.84

Chronic Obstructive Pulmonary Disease heterogeneity: challenges for health risk assessment, stratification and management. J Transl Med (2014) 0.81

Predictive medicine: outcomes, challenges and opportunities in the Synergy-COPD project. J Transl Med (2014) 0.80

Diagnosis, assessment, and phenotyping of COPD: beyond FEV1. Int J Chron Obstruct Pulmon Dis (2016) 0.80

Meta-analysis of routine blood tests as predictors of mortality in COPD. Eur Clin Respir J (2014) 0.79

Exhaled volatile organic compounds discriminate patients with chronic obstructive pulmonary disease from healthy subjects. Int J Chron Obstruct Pulmon Dis (2015) 0.78

Physical inactivity and arterial stiffness in COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.78

Czech multicenter research database of severe COPD. Int J Chron Obstruct Pulmon Dis (2014) 0.77

Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies. COPD (2016) 0.75

Alterations in Serum Polyunsaturated Fatty Acids and Eicosanoids in Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD). Int J Mol Sci (2016) 0.75

Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management? Int J Chron Obstruct Pulmon Dis (2016) 0.75

Mid-regional pro-adrenomedullin and copeptin to predict short-term prognosis of COPD exacerbations: a multicenter prospective blinded study. Int J Chron Obstruct Pulmon Dis (2017) 0.75

Loss of Peripheral Tolerance in Emphysema. Phenotypes, Exacerbations, and Disease Progression. Ann Am Thorac Soc (2015) 0.75

The association between risk of airflow limitation and serum uric acid measured at medical health check-ups. Int J Chron Obstruct Pulmon Dis (2017) 0.75

COPD exacerbations by disease severity in England. Int J Chron Obstruct Pulmon Dis (2016) 0.75

Impaired Blood Neutrophil Function in the Frequent Exacerbator of Chronic Obstructive Pulmonary Disease: A Proof-of-Concept Study. Lung (2016) 0.75

Predictors of Hospitalized Exacerbations and Mortality in Chronic Obstructive Pulmonary Disease. PLoS One (2016) 0.75

Assisted ventilation in COPD - association between previous hospitalizations and mortality. Int J Chron Obstruct Pulmon Dis (2016) 0.75

Biomarkers of extracellular matrix turnover are associated with emphysema and eosinophilic-bronchitis in COPD. Respir Res (2017) 0.75

Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D. PLoS One (2017) 0.75

Clinical characteristics of chronic bronchitic, emphysematous and ACOS phenotypes in COPD patients with frequent exacerbations. Int J Chron Obstruct Pulmon Dis (2017) 0.75

Articles by these authors

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med (2007) 19.86

A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med (2008) 17.19

Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA (2006) 10.54

Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med (2007) 8.06

Sequencing of Aspergillus nidulans and comparative analysis with A. fumigatus and A. oryzae. Nature (2005) 7.74

Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 7.67

Genetic epidemiology of COPD (COPDGene) study design. COPD (2010) 7.67

High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2005) 7.20

A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet (2009) 6.93

Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med (2014) 6.29

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med (2008) 6.17

Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med (2011) 5.69

American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med (2006) 5.65

Family-based tests for associating haplotypes with general phenotype data: application to asthma genetics. Genet Epidemiol (2004) 5.57

Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med (2012) 5.54

Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet (2009) 5.51

Genomic screening and replication using the same data set in family-based association testing. Nat Genet (2005) 5.44

Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res (2010) 5.17

Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature (2011) 4.92

Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med (2011) 4.75

Diesel exhaust inhalation causes vascular dysfunction and impaired endogenous fibrinolysis. Circulation (2005) 4.71

PBAT: tools for family-based association studies. Am J Hum Genet (2004) 4.68

An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med (2013) 4.49

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet (2009) 4.40

Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med (2009) 4.27

Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19

Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med (2015) 4.16

GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98

MMP12, lung function, and COPD in high-risk populations. N Engl J Med (2009) 3.96

Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet (2009) 3.93

An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2010) 3.92

Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest (2010) 3.91

The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology (2002) 3.91

A genome-wide association study of pulmonary function measures in the Framingham Heart Study. PLoS Genet (2009) 3.78

Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J (2004) 3.77

Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 3.70

Systemic effects of smoking. Chest (2007) 3.63

Living and dying with severe chronic obstructive pulmonary disease: multi-perspective longitudinal qualitative study. BMJ (2011) 3.61

Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med (2011) 3.58

Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 3.54

A multivariate family-based association test using generalized estimating equations: FBAT-GEE. Biostatistics (2003) 3.52

Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet (2010) 3.44

Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med (2012) 3.44

Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene. Am J Hum Genet (2009) 3.41

What is chronic obstructive pulmonary disease anyway?: Continua, categories, cut points, and moving beyond spirometry. Am J Respir Crit Care Med (2013) 3.39

On the replication of genetic associations: timing can be everything! Am J Hum Genet (2008) 3.32

Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology (2011) 3.30

Combustion-derived nanoparticles: a review of their toxicology following inhalation exposure. Part Fibre Toxicol (2005) 3.12

Adverse cardiovascular effects of air pollution. Nat Clin Pract Cardiovasc Med (2008) 3.00

The SERPINE2 gene is associated with chronic obstructive pulmonary disease in two large populations. Am J Respir Crit Care Med (2007) 2.91